Cover Image
市場調查報告書

Immune Response BioPharma, Inc. 的產品平台分析

Immune Response BioPharma, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319979
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Immune Response BioPharma, Inc. 的產品平台分析 Immune Response BioPharma, Inc. - Product Pipeline Review - 2015
出版日期: 2015年12月16日 內容資訊: 英文 42 Pages
簡介

Immune Response BioPharma, Inc.總公司在美國的製藥企業,開發自體免疫疾病和感染疾病的疫苗。該公司的產品使用於多發性硬化症、肺血性休克、HIV/AIDS、類風濕性關節炎、克隆氏症、乾癬等、痛風和糖尿病、心臟疾病等的治療。

本報告提供Immune Response BioPharma, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Immune Response BioPharma, Inc. 的基本資料

  • Immune Response BioPharma, Inc. 概要
  • 主要資訊
  • 企業資料

Immune Response BioPharma, Inc. :R&D概要

  • 主要的治療範圍

Immune Response BioPharma, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Immune Response BioPharma, Inc. :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Immune Response BioPharma, Inc. :藥物簡介

  • IR-103
  • IR-501
  • IR-703
  • IR-502
  • IR-902
  • RemuneX
  • IR-007
  • IR-1000
  • IR-1002
  • IR-2020
  • IR-222
  • IR-444
  • IR-555
  • IR-777
  • IR-888
  • IR-999

Immune Response BioPharma, Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型

Immune Response BioPharma, Inc. :最近的開發平台資訊

Immune Response BioPharma, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07861CDB

Summary

Global Markets Direct's, 'Immune Response BioPharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Immune Response BioPharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immune Response BioPharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Immune Response BioPharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Immune Response BioPharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Immune Response BioPharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Immune Response BioPharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Immune Response BioPharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Immune Response BioPharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Immune Response BioPharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immune Response BioPharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Immune Response BioPharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immune Response BioPharma, Inc. Snapshot
    • Immune Response BioPharma, Inc. Overview
    • Key Information
    • Key Facts
  • Immune Response BioPharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Immune Response BioPharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Immune Response BioPharma, Inc. - Pipeline Products Glance
    • Immune Response BioPharma, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Immune Response BioPharma, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immune Response BioPharma, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Immune Response BioPharma, Inc. - Drug Profiles
    • REMUNE
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-502
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-902
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-777
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-1000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-1002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-2020
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-222
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-444
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-555
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-888
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IR-999
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IRE-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IRR-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IRS-103
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immune Response BioPharma, Inc. - Pipeline Analysis
    • Immune Response BioPharma, Inc. - Pipeline Products by Target
    • Immune Response BioPharma, Inc. - Pipeline Products by Route of Administration
    • Immune Response BioPharma, Inc. - Pipeline Products by Molecule Type
  • Immune Response BioPharma, Inc. - Recent Pipeline Updates
  • Immune Response BioPharma, Inc. - Dormant Projects
  • Immune Response BioPharma, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immune Response BioPharma, Inc., Key Information
  • Immune Response BioPharma, Inc., Key Facts
  • Immune Response BioPharma, Inc. - Pipeline by Indication, 2015
  • Immune Response BioPharma, Inc. - Pipeline by Stage of Development, 2015
  • Immune Response BioPharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Immune Response BioPharma, Inc. - Pre-Registration, 2015
  • Immune Response BioPharma, Inc. - Phase II, 2015
  • Immune Response BioPharma, Inc. - Phase I, 2015
  • Immune Response BioPharma, Inc. - Preclinical, 2015
  • Immune Response BioPharma, Inc. - Pipeline by Target, 2015
  • Immune Response BioPharma, Inc. - Pipeline by Route of Administration, 2015
  • Immune Response BioPharma, Inc. - Pipeline by Molecule Type, 2015
  • Immune Response BioPharma, Inc. - Recent Pipeline Updates, 2015
  • Immune Response BioPharma, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Immune Response BioPharma, Inc. - Pipeline by Top 10 Indication, 2015
  • Immune Response BioPharma, Inc. - Pipeline by Stage of Development, 2015
  • Immune Response BioPharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Immune Response BioPharma, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Immune Response BioPharma, Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top